# US 2019/0056392 A1 · Methods for the diagnostic of an autoimmune disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0056392 A1
- Document ID: US20190056392A1
- Status: Published application
- Kind: A1
- Application number: 16/143,896
- Filed: 2018-09-27
- Published: 2019-02-21
- Earliest claimed: 2014-04-22
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Institut Curie; Universite Paris Descartes; Centre National de la Recherche Scientifique (CNRS)
- Applicants: Inserm (Institut National De La Santé Et De La Recherche MéDicale); Institut Curie; Universite Paris Descartes; Centre National De La Recherche Scientifique (Cnrs)
- Inventors: Eliane PIAGGIO; Louis PEROL
- Web page: https://patentgrep.com/patent/US20190056392A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- C07K 14/55: IL-2
- C07K 16/246: {IL-2}
- G01N 33/00: Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- G01N 2333/55: IL-2
- G01N 2800/24: Immunology or allergic disorders
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An in vitro method for determining whether a patient has, or is at risk of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, comprising a step of detecting or quantifying in a biological sample obtained from said patient an immune anti-IL2 response, peptides specifically recognised by anti-1L2 antibodies or IL-2-specific T cells of T1D, systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome and autoimmune polymyositis patients, and pharmaceutical compositions.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

An in vitro method for determining whether a patient has, or is at risk, of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, wherein said in vitro method comprises a step of detecting or quantifying, in a biological sample obtained from said patient, an immune anti-IL-2 response.

### Claim 17 (depends on 16)

The in vitro method according to claim 16, wherein immune anti-IL2 response is evidenced by the detection or quantification of one or more of:
B cells producing anti-IL-2 AutoAbs;
anti-IL-2 antibodies; and
IL-2-specific T-cells.

### Claim 18 (depends on 17)

The in vitro method according to claim 17, wherein immune anti-IL2 response is evidenced by the detection or quantification of B cells producing anti-IL-2 AutoAbs or anti-IL-2 antibodies, wherein the AutoAbs are neutralizing anti-IL-2 AutoAbs.

### Claim 19 (depends on 17)

The in vitro method according to claim 17, wherein the detection or quantification of one or more of B cells producing anti-IL-2 AutoAbs, anti-IL-2 antibodies; and IL-2-specific T-cells comprises a step of using a peptide consisting of amino acid sequence:
(SEQ ID No 1)
LTRMLTFKFYMPKKA,
or
(SEQ ID No 2)
EFLNRWITFSQSIIS.

### Claim 20 (depends on 16)

The in vitro method according to claim 16, wherein the autoimmune disease is selected from the group consisting of type 1 diabetes (T1D), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SJO) and autoimmune polymyositis (JO1).

### Claim 21 (depends on 16)

The in vitro method according to claim 16, wherein the method is a method for determining whether a patient has, or is at risk of having or developing, an autoimmune disease.

### Claim 22 (depends on 16)

The in vitro method according to claim 16, wherein the method is a method for assessing the severity of an autoimmune disease.

### Claim 23 (depends on 16)

The in vitro method according to claim 16, wherein the method is a method for predicting the outcome of an autoimmune disease.

### Claim 24 (depends on 16)

The in vitro method according to claim 16, wherein the method is a method for predicting/adjusting the response to exogenously administered IL-2 for therapeutic purposes.
